BACKGROUND: We evaluated the association between maternal antiretrovirals (ARVs) during pregnancy and infant congenital anomalies (CAs), utilizing data from the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. METHODS: The study population consisted of first singleton pregnancies on study, > or =20 weeks gestation, among women enrolled in NISDI from Argentina and Brazil who delivered between September 2002 and October 2007. CAs were defined as any major structural or chromosomal abnormality, or a cluster of 2 or more minor abnormalities, according to the conventions of the Antiretroviral Pregnancy Registry. CAs were identified from fetal ultrasound, study visit, and death reports. Prevalence rates [number of CAs per 100 live births (LBs)] were calculated for specific ARVs, classes of ARVs, and overall exposure to ARVs. RESULTS: Of 1229 women enrolled, 995 pregnancy outcomes (974 LBs) met the inclusion criteria. Of these, 60 infants (59 LBs and 1 stillbirth) had at least 1 CA. The overall prevalence of CAs (per 100 LBs) was 6.2 [95% confidence interval (CI) 4.6 to 7.7]. The prevalence of CAs after first trimester ARVs (6.2; 95% CI 3.1 to 9.3) was similar to that after second (6.8; 95% CI 4.5 to 9.0) or third trimester (4.3; 95% CI 1.5 to 7.2) exposure. The rate of CAs identified within 7 days of delivery was 2.36 (95% CI 1.4 to 3.3). CONCLUSIONS: The prevalence of CAs after first trimester exposure to ARVs was similar to that after second or third trimester exposure. Continued surveillance for CAs among children exposed to ARVs during gestation is needed.
BACKGROUND: We evaluated the association between maternal antiretrovirals (ARVs) during pregnancy and infantcongenital anomalies (CAs), utilizing data from the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. METHODS: The study population consisted of first singleton pregnancies on study, > or =20 weeks gestation, among women enrolled in NISDI from Argentina and Brazil who delivered between September 2002 and October 2007. CAs were defined as any major structural or chromosomal abnormality, or a cluster of 2 or more minor abnormalities, according to the conventions of the Antiretroviral Pregnancy Registry. CAs were identified from fetal ultrasound, study visit, and death reports. Prevalence rates [number of CAs per 100 live births (LBs)] were calculated for specific ARVs, classes of ARVs, and overall exposure to ARVs. RESULTS: Of 1229 women enrolled, 995 pregnancy outcomes (974 LBs) met the inclusion criteria. Of these, 60 infants (59 LBs and 1 stillbirth) had at least 1 CA. The overall prevalence of CAs (per 100 LBs) was 6.2 [95% confidence interval (CI) 4.6 to 7.7]. The prevalence of CAs after first trimester ARVs (6.2; 95% CI 3.1 to 9.3) was similar to that after second (6.8; 95% CI 4.5 to 9.0) or third trimester (4.3; 95% CI 1.5 to 7.2) exposure. The rate of CAs identified within 7 days of delivery was 2.36 (95% CI 1.4 to 3.3). CONCLUSIONS: The prevalence of CAs after first trimester exposure to ARVs was similar to that after second or third trimester exposure. Continued surveillance for CAs among children exposed to ARVs during gestation is needed.
Authors: Eduardo E Castilla; Iêda M Orioli; Jorge S Lopez-Camelo; Maria da Graça Dutra; Julio Nazer-Herrera Journal: Am J Med Genet A Date: 2003-12-01 Impact factor: 2.802
Authors: L Stewart Massad; Gayle Springer; Lisa Jacobson; Heather Watts; Kathryn Anastos; Abner Korn; Helen Cejtin; Alice Stek; Mary Young; Julie Schmidt; Howard Minkoff Journal: AIDS Date: 2004-01-23 Impact factor: 4.177
Authors: Claire L Townsend; Barbara A Willey; Mario Cortina-Borja; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Jennifer S Read; Geraldo Duarte; Laura Freimanis Hance; Jorge Pinto; Maria I Gouvea; Rachel A Cohen; Breno Santos; Elizabete Teles; Regina Succi; Jorge Alarcon; Sonia K Stoszek Journal: Int J Epidemiol Date: 2011-02-27 Impact factor: 7.196
Authors: Katherine M Knapp; Susan B Brogly; Daniel G Muenz; Hans M L Spiegel; Daniel H Conway; Gwendolyn B Scott; Jeffrey T Talbot; David E Shapiro; Jennifer S Read Journal: Pediatr Infect Dis J Date: 2012-02 Impact factor: 2.129
Authors: Kelesitse Phiri; Sonia Hernandez-Diaz; Kate B Dugan; Paige L Williams; Judith A Dudley; Astride Jules; S Todd Callahan; George R Seage; William O Cooper Journal: Pediatr Infect Dis J Date: 2014-07 Impact factor: 2.129
Authors: Kathryn Rough; Jenny W Sun; George R Seage; Paige L Williams; Krista F Huybrechts; Brian T Bateman; Sonia Hernandez-Diaz Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Esaú C João; R Leavitt Morrison; David E Shapiro; Nahida Chakhtoura; Maria Isabel S Gouvèa; Maria de Lourdes B Teixeira; Trevon L Fuller; Blandina T Mmbaga; James S Ngocho; Boniface N Njau; Avy Violari; Ruth Mathiba; Zaakirah Essack; Jose Henrique S Pilotto; Luis Felipe Moreira; Maria Jose Rolon; Pedro Cahn; Sinart Prommas; Timothy R Cressey; Kulkanya Chokephaibulkit; Peerawong Werarak; Lauren Laimon; Roslyn Hennessy; Lisa M Frenkel; Patricia Anthony; Brookie M Best; George K Siberry; Mark Mirochnick Journal: Lancet HIV Date: 2020-05 Impact factor: 12.767
Authors: Paige L Williams; Marilyn J Crain; Cenk Yildirim; Rohan Hazra; Russell B Van Dyke; Kenneth Rich; Jennifer S Read; Emma Stuard; Mobeen Rathore; Hermann A Mendez; D Heather Watts Journal: JAMA Pediatr Date: 2015-01 Impact factor: 16.193
Authors: Karin Nielsen-Saines; Lauren Komarow; Susan Cu-Uvin; Gonzague Jourdain; Karin L Klingman; David E Shapiro; Lynne Mofenson; Laura Moran; Thomas B Campbell; Jane Hitti; Susan Fiscus; Judith Currier Journal: Pediatrics Date: 2012-05-14 Impact factor: 7.124